Previous section Next section
The investment stage of glycolysis
Body_ID: HC011005
Glucose-6-phosphate
Body_ID: HC011006
Glucose is taken up into the red cell via the facilitated transporter, GLUT-1 (Chapter 7); this protein accounts for approximately 5% of total red cell membrane protein, so that transport is not rate limiting for glycolysis. The first step in the commitment of glucoseView drug information to glycolysis is the phosphorylation of glucoseView drug information to Glc-6-P, catalyzed by the enzyme hexokinase (Fig. 11.3, top). The formation of Glc-6-P from free glucoseView drug information and inorganic phosphate is energetically unfavorable, so that a molecule of ATP must be expended or invested in the phosphorylation reaction - the hydrolysis of ATP is coupled to the synthesis of Glc-6-P. The Glc-6-P is trapped in the RBC, along with other phosphorylated intermediates in glycolysis, because there are no transport systems for sugar phosphates in the plasma membranes of mammalian cells.
Body_ID: P011010
GLUCOSE UTILIZATION IN THE RED CELL
Body_ID: B011001
In a 70-kg person, there are about 5 L of blood and a little over 2 kg (2 L) of RBCs. These cells constitute about 3% of total body mass and consume about 20 g (0.1 mole) of glucoseView drug information per day, representing about 10% of total body glucoseView drug information metabolism. The RBC has the highest specific rate of glucoseView drug information utilization of any cell in the body, approximately 10 g of glucose/kg of tissue/day, compared with ∼2.5 g of glucose/kg of tissue/day for the whole body.
Body_ID: PB11001
In the RBC, about 90% of glucoseView drug information (∼18 g or 0.1 mole) is metabolized via glycolysis, yielding ∼0.2 mole of lactate (∼18 g/day). Despite its high rate of glucoseView drug information consumption, the RBC has one of the lowest rates of ATP synthesis of any cell in the body, ∼0.2 mole of ATP per day, reflecting the fact that most of its glucoseView drug information metabolism is carried out by anaerobic glycolysis, which produces lactate and traps only a fraction of the energy available from complete combustion of glucoseView drug information to CO2 and H2O.
Body_ID: PB11002
page 144
0
page 145
Body_ID: P0145
Body_ID: P011011
Body_ID: F011002
Figure 11.2 Interactions between glycolysis and other metabolic pathways. The green colored boxes indicate intermediates involved in the pathway of glycolysis. Other boxes illustrate some of the metabolic interactions between glycolysis and other metabolic pathways in the cell. Not all of these pathways are active in the red cell which has limited biosynthetic capacity and lacks mitochondria. Glc-6-P, glucose-6-phosphate; Fru-6-P, fructose-6-phosphate; Fru-1,6-BP, fructose-1,6-bisphosphate.
Fructose-6-phosphate
Body_ID: HC011007
The second step in glycolysis is the conversion of Glc-6-P into Fru-6-P by phosphoglucose isomerase (Fig. 11.3, middle). Isomerases catalyze freely reversible equilibrium reactions, in this case an aldose-ketose interconversion. The Fru-6-P can now be phosphorylated at C-1 by phosphofructokinase-1 (PFK-1) to yield the pseudosymmetric intermediate, fructose 1,6-bisphosphate (Fru-1,6-BP), which has a phosphate ester on each end of the molecule. PFK-1 requires ATP as a substrate and, like hexokinase, catalyzes an essentially irreversible reaction (Keq ≈ 500). Both hexokinase and PFK-1 are important regulatory enzymes in glycolysis, but PFK-1 is the critical step. This reaction commits glucoseView drug information to glycolysis, the only pathway for metabolism of Fru-1,6-BP.
Body_ID: P011012
page 145
0
page 146
Body_ID: P0146
Body_ID: P011013
Body_ID: F011003
Figure 11.3 The investment and splitting stages of glycolysis. Note the consumption of ATP at the hexokinase and phosphofructokinase-1 reactions.
Previous section
Bar end Bar end
Next section
Copyright © 2007 Elsevier Inc. All rights reserved. Read our Terms and Conditions of Use and our Privacy Policy.
For problems or suggestions concerning this service, please contact: studentconsult.help@elsevier.com